Implications of reactive oxygen species on cancer formation and its treatment
Elevated levels of reactive oxygen species (ROS) are a hallmark of cancer. Although increased ROS concentrations play important roles in cancer formation and progression, levels above a cytotoxic threshold cause cancer cell death. Cancer cells adapt to high concentrations of ROS via antioxidant prod...
Uložené v:
| Vydané v: | Seminars in oncology Ročník 48; číslo 3; s. 238 |
|---|---|
| Hlavní autori: | , |
| Médium: | Journal Article |
| Jazyk: | English |
| Vydavateľské údaje: |
United States
01.06.2021
|
| Predmet: | |
| ISSN: | 1532-8708, 1532-8708 |
| On-line prístup: | Zistit podrobnosti o prístupe |
| Tagy: |
Pridať tag
Žiadne tagy, Buďte prvý, kto otaguje tento záznam!
|
| Abstract | Elevated levels of reactive oxygen species (ROS) are a hallmark of cancer. Although increased ROS concentrations play important roles in cancer formation and progression, levels above a cytotoxic threshold cause cancer cell death. Cancer cells adapt to high concentrations of ROS via antioxidant production and reprogrammed cellular metabolism (eg, the Warburg effect). Because some widely used anticancer therapies such as radiation therapy and chemotherapy rely on ROS accumulation as a mechanism to induce cancer cell death, a cancer cell's ability to control ROS levels is a driver of treatment resistance and a critical consideration for successful cancer treatment. The necessity for cancer cells to adapt to elevated levels of ROS to survive may represent an Achilles heel for some malignancies, as therapies designed to interfere with this adaptation would be expected to kill cancer cells. In this review, we provide an overview of the implications of ROS on cancer formation and anticancer treatment strategies, with a focus on treatment-resistant disease. |
|---|---|
| AbstractList | Elevated levels of reactive oxygen species (ROS) are a hallmark of cancer. Although increased ROS concentrations play important roles in cancer formation and progression, levels above a cytotoxic threshold cause cancer cell death. Cancer cells adapt to high concentrations of ROS via antioxidant production and reprogrammed cellular metabolism (eg, the Warburg effect). Because some widely used anticancer therapies such as radiation therapy and chemotherapy rely on ROS accumulation as a mechanism to induce cancer cell death, a cancer cell's ability to control ROS levels is a driver of treatment resistance and a critical consideration for successful cancer treatment. The necessity for cancer cells to adapt to elevated levels of ROS to survive may represent an Achilles heel for some malignancies, as therapies designed to interfere with this adaptation would be expected to kill cancer cells. In this review, we provide an overview of the implications of ROS on cancer formation and anticancer treatment strategies, with a focus on treatment-resistant disease.Elevated levels of reactive oxygen species (ROS) are a hallmark of cancer. Although increased ROS concentrations play important roles in cancer formation and progression, levels above a cytotoxic threshold cause cancer cell death. Cancer cells adapt to high concentrations of ROS via antioxidant production and reprogrammed cellular metabolism (eg, the Warburg effect). Because some widely used anticancer therapies such as radiation therapy and chemotherapy rely on ROS accumulation as a mechanism to induce cancer cell death, a cancer cell's ability to control ROS levels is a driver of treatment resistance and a critical consideration for successful cancer treatment. The necessity for cancer cells to adapt to elevated levels of ROS to survive may represent an Achilles heel for some malignancies, as therapies designed to interfere with this adaptation would be expected to kill cancer cells. In this review, we provide an overview of the implications of ROS on cancer formation and anticancer treatment strategies, with a focus on treatment-resistant disease. Elevated levels of reactive oxygen species (ROS) are a hallmark of cancer. Although increased ROS concentrations play important roles in cancer formation and progression, levels above a cytotoxic threshold cause cancer cell death. Cancer cells adapt to high concentrations of ROS via antioxidant production and reprogrammed cellular metabolism (eg, the Warburg effect). Because some widely used anticancer therapies such as radiation therapy and chemotherapy rely on ROS accumulation as a mechanism to induce cancer cell death, a cancer cell's ability to control ROS levels is a driver of treatment resistance and a critical consideration for successful cancer treatment. The necessity for cancer cells to adapt to elevated levels of ROS to survive may represent an Achilles heel for some malignancies, as therapies designed to interfere with this adaptation would be expected to kill cancer cells. In this review, we provide an overview of the implications of ROS on cancer formation and anticancer treatment strategies, with a focus on treatment-resistant disease. |
| Author | Rogoff, Harry A Shah, Manish A |
| Author_xml | – sequence: 1 givenname: Manish A surname: Shah fullname: Shah, Manish A email: mas9313@med.cornell.edu organization: Weill Cornell Medicine, New York-Presbyterian Hospital, New York, NY, USA. Electronic address: mas9313@med.cornell.edu – sequence: 2 givenname: Harry A surname: Rogoff fullname: Rogoff, Harry A organization: Sumitomo Dainippon Pharma Oncology, Inc., Cambridge, MA, USA |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/34548190$$D View this record in MEDLINE/PubMed |
| BookMark | eNpNkMtOwzAQRS1URB_wC8hLNgm2E8fuElU8KhWxgXXk2mPkKrFD7CD691hQJFZzZ-bcO9Is0cwHDwhhSkpKeHV7KCP0Lg916EpGGC0JLwlhZ2hBecUKKYic_dNztIzxkAEqGLtA86rmtaRrskDP237onFbJBR9xsHgEpZP7BBy-ju_gcRxAO8grj7XyGkZsw9j_8Fh5g12KOGVT6sGnS3RuVRfh6lRX6O3h_nXzVOxeHrebu12h89lUmL3hylrJaq4pA0FMJXXV5E5KTZTg1VrAnnNRa2EVa7gxVa1BUmK0FcSyFbr5zR3G8DFBTG3vooauUx7CFFvGc0YjaMMzen1Cp30Pph1G16vx2P69gH0DdEJj7g |
| CitedBy_id | crossref_primary_10_1016_j_bcp_2025_117191 crossref_primary_10_1016_j_jconrel_2022_08_008 crossref_primary_10_1002_adma_202301810 crossref_primary_10_3389_fimmu_2022_1051998 crossref_primary_10_1021_jacs_3c09339 crossref_primary_10_3390_ijms26157513 crossref_primary_10_3389_fonc_2023_1200619 crossref_primary_10_1186_s13048_025_01725_z crossref_primary_10_2147_IJN_S399026 crossref_primary_10_1155_2022_8972730 crossref_primary_10_3390_biomedicines13030665 crossref_primary_10_1002_cbdv_202402436 crossref_primary_10_1038_s41580_023_00645_4 crossref_primary_10_1038_s41598_025_85856_9 crossref_primary_10_3390_diseases13010022 crossref_primary_10_3892_or_2024_8833 crossref_primary_10_1007_s43188_024_00246_z crossref_primary_10_3390_cancers14194562 crossref_primary_10_3390_cancers15071936 crossref_primary_10_1007_s12032_025_02714_4 crossref_primary_10_3390_foods13060958 crossref_primary_10_1155_2024_4953859 crossref_primary_10_1007_s11033_024_09662_8 crossref_primary_10_3390_antiox13020213 crossref_primary_10_1002_slct_202405905 crossref_primary_10_3390_antiox14060620 crossref_primary_10_1002_cnr2_70044 crossref_primary_10_1016_j_critrevonc_2025_104894 crossref_primary_10_1016_j_taap_2025_117333 crossref_primary_10_3390_ijms26094173 crossref_primary_10_1016_j_clcc_2022_11_002 crossref_primary_10_3390_ijms26188869 crossref_primary_10_1089_ars_2023_0491 crossref_primary_10_1007_s12032_022_01900_y crossref_primary_10_1161_JAHA_125_042534 crossref_primary_10_1016_j_fbio_2025_106985 crossref_primary_10_1016_j_abb_2024_110261 crossref_primary_10_1007_s12010_025_05346_6 crossref_primary_10_1016_j_jinorgbio_2022_111983 crossref_primary_10_3390_ijms25084505 crossref_primary_10_2217_bmm_2022_0846 crossref_primary_10_1016_j_hermed_2024_100969 crossref_primary_10_1016_j_jddst_2024_105584 crossref_primary_10_3389_fpubh_2025_1544174 crossref_primary_10_1002_slct_202301826 crossref_primary_10_3390_cancers17122050 crossref_primary_10_1002_adma_202307337 crossref_primary_10_1016_j_biopha_2024_116386 crossref_primary_10_2147_IJN_S467733 crossref_primary_10_1186_s11671_025_04248_0 crossref_primary_10_32604_or_2024_031006 crossref_primary_10_3390_pharmaceutics14091808 crossref_primary_10_1007_s00210_023_02673_5 crossref_primary_10_1039_D4SC01625D crossref_primary_10_1002_jmr_70005 crossref_primary_10_1002_advs_202308307 crossref_primary_10_1007_s00204_024_03861_9 crossref_primary_10_1016_j_toxicon_2023_107179 crossref_primary_10_1186_s42269_022_00943_5 crossref_primary_10_1016_j_intimp_2024_112818 crossref_primary_10_1016_j_jddst_2023_105053 crossref_primary_10_3390_polym15081962 crossref_primary_10_1007_s00018_025_05670_4 crossref_primary_10_1016_j_biopha_2025_118355 crossref_primary_10_1016_j_jafr_2025_102315 crossref_primary_10_3390_ijms25010280 crossref_primary_10_1016_j_biocel_2024_106697 crossref_primary_10_3390_biom13091296 crossref_primary_10_1016_j_cej_2024_157825 crossref_primary_10_1016_j_archoralbio_2023_105780 crossref_primary_10_1038_s41388_024_03222_x crossref_primary_10_3390_ijms25158276 crossref_primary_10_1039_D5MH01000D crossref_primary_10_32604_or_2023_042384 crossref_primary_10_3390_metabo13070796 crossref_primary_10_1016_j_cellsig_2025_111754 crossref_primary_10_1016_j_jinorgbio_2024_112770 crossref_primary_10_3390_cancers17060938 |
| ContentType | Journal Article |
| Copyright | Copyright © 2021. Published by Elsevier Inc. |
| Copyright_xml | – notice: Copyright © 2021. Published by Elsevier Inc. |
| DBID | CGR CUY CVF ECM EIF NPM 7X8 |
| DOI | 10.1053/j.seminoncol.2021.05.002 |
| DatabaseName | Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed MEDLINE - Academic |
| DatabaseTitle | MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) MEDLINE - Academic |
| DatabaseTitleList | MEDLINE - Academic MEDLINE |
| Database_xml | – sequence: 1 dbid: NPM name: PubMed url: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: 7X8 name: MEDLINE - Academic url: https://search.proquest.com/medline sourceTypes: Aggregation Database |
| DeliveryMethod | no_fulltext_linktorsrc |
| Discipline | Medicine |
| EISSN | 1532-8708 |
| ExternalDocumentID | 34548190 |
| Genre | Journal Article Review |
| GroupedDBID | --- --K .1- .55 .FO .GJ 0R~ 123 1P~ 3O- 4.4 457 4CK 53G 5RE AAEDW AALRI AAQOH AAQQT AAQXK AAWTL AAXUO ABFRF ABJNI ABOCM ABUDA ABWVN ACGFO ACRPL ADBBV ADMUD ADNMO AEFWE AENEX AEVXI AFCTW AFETI AFFNX AFJKZ AFRHN AFTJW AGHFR AGRDE AITUG AJUYK ALMA_UNASSIGNED_HOLDINGS AMRAJ ASPBG AVWKF AZFZN CGR CS3 CUY CVF DU5 EBS ECM EIF EJD F5P FDB FEDTE FGOYB GBLVA HVGLF HZ~ IH2 J5H K-O L7B MJL N4W NPM O9- OC~ OO- P2P R2- RIG ROL SEL SES SJN TWZ UDS X7M Z5R ZGI ZXP 7X8 APXCP |
| ID | FETCH-LOGICAL-c481t-dbd5aff8245c12e70d38c3645c88c0a75397eb5574c7fa265dd34ce810dcf70f2 |
| IEDL.DBID | 7X8 |
| ISICitedReferencesCount | 91 |
| ISICitedReferencesURI | http://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=Summon&SrcAuth=ProQuest&DestLinkType=CitingArticles&DestApp=WOS_CPL&KeyUT=000718024500006&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D |
| ISSN | 1532-8708 |
| IngestDate | Fri Sep 05 10:25:34 EDT 2025 Thu Jan 02 22:54:52 EST 2025 |
| IsDoiOpenAccess | false |
| IsOpenAccess | true |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 3 |
| Keywords | treatment cancer drug resistance reduction-oxidation balance reactive oxygen species |
| Language | English |
| License | Copyright © 2021. Published by Elsevier Inc. |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-c481t-dbd5aff8245c12e70d38c3645c88c0a75397eb5574c7fa265dd34ce810dcf70f2 |
| Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 ObjectType-Review-3 content type line 23 |
| OpenAccessLink | https://doi.org/10.1053/j.seminoncol.2021.05.002 |
| PMID | 34548190 |
| PQID | 2575367165 |
| PQPubID | 23479 |
| ParticipantIDs | proquest_miscellaneous_2575367165 pubmed_primary_34548190 |
| PublicationCentury | 2000 |
| PublicationDate | 2021-06-00 20210601 |
| PublicationDateYYYYMMDD | 2021-06-01 |
| PublicationDate_xml | – month: 06 year: 2021 text: 2021-06-00 |
| PublicationDecade | 2020 |
| PublicationPlace | United States |
| PublicationPlace_xml | – name: United States |
| PublicationTitle | Seminars in oncology |
| PublicationTitleAlternate | Semin Oncol |
| PublicationYear | 2021 |
| SSID | ssj0021722 |
| Score | 2.597277 |
| SecondaryResourceType | review_article |
| Snippet | Elevated levels of reactive oxygen species (ROS) are a hallmark of cancer. Although increased ROS concentrations play important roles in cancer formation and... |
| SourceID | proquest pubmed |
| SourceType | Aggregation Database Index Database |
| StartPage | 238 |
| SubjectTerms | Antineoplastic Agents - pharmacology Antineoplastic Agents - therapeutic use Humans Neoplasms - drug therapy Neoplasms - pathology Oxidative Stress Reactive Oxygen Species - metabolism Reactive Oxygen Species - pharmacology Reactive Oxygen Species - therapeutic use |
| Title | Implications of reactive oxygen species on cancer formation and its treatment |
| URI | https://www.ncbi.nlm.nih.gov/pubmed/34548190 https://www.proquest.com/docview/2575367165 |
| Volume | 48 |
| WOSCitedRecordID | wos000718024500006&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D |
| hasFullText | |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| link | http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV1JS8QwFA7qiHhxX8aNCF7rtFma5CQiDgrOMAeVuZVOFpiD7Titov_el7ZTvQiCl9wCycuXl-9teQhdEBv7V9UGsWI0YFzoYGKogiFKneAqTqsK7-cHMRzK8ViNGodb0aRVLnRipahNrr2PvAfQ4jQGds-vZq-B7xrlo6tNC41l1KFAZTyqxbiNIvjeS6T-L9Xf-lA2mTyAu56v6H6ZgoUN4gYrkUSXrXPlF6JZPTj9zf8udQttNFQTX9fY2EZLNttBa4MmmL6LBvc_sslx7jDwx0r74fzjE3CFfRUmGNI4z7D24JjjttQRp5nB07LAbaL6Hnrq3z7e3AVNd4VAMxmVgZkYnjonCeM6IlaEhkrtg5JaSh2msAUl7IRzwbRwKYm5MZRpK6PQaCdCR_bRCsjPHiIsCJPMKKVjEzJGGMzSXEVOxsLZiLouOl8IKgH0-pBEmtn8rUi-RdVFB7W0k1n9zUZCGVhTwFeO_jD7GK37Q6xzuE5Qx8HdtadoVb-X02J-VsECxuFo8AVXxcJJ |
| linkProvider | ProQuest |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Implications+of+reactive+oxygen+species+on+cancer+formation+and+its+treatment&rft.jtitle=Seminars+in+oncology&rft.au=Shah%2C+Manish+A&rft.au=Rogoff%2C+Harry+A&rft.date=2021-06-01&rft.eissn=1532-8708&rft.volume=48&rft.issue=3&rft.spage=238&rft_id=info:doi/10.1053%2Fj.seminoncol.2021.05.002&rft_id=info%3Apmid%2F34548190&rft_id=info%3Apmid%2F34548190&rft.externalDocID=34548190 |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1532-8708&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1532-8708&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1532-8708&client=summon |